Old and new concepts in the world of pulmonary vascular medicine
DAY 2
Chaired by: Nicola Speed (Cambridge) and Dr Rachel Davies (London)
10.30am - Can we treat lung disease related PH yet? Dr Colin Church (Glasgow)
11.00am - Changing landscapes of therapeutics in pulmonary arterial hypertension Dr Colm McCabe (London)
11.30am - Chronic Thromboembolic Pulmonary vascular disease in 2026: where are we and where are we going? Dr Katherine Bunclark (Cambridge)
10:30 AM
90 MINUTE SESSION
Learning outcomes
The management of patients with pulmonary hypertension associated lung disease is rapidly changing. This talk will explore which patients to refer to a designated PH centre as well as discuss the trial evidence for treatment of PH-associated lung disease.
With the advent of the first disease modifying treatment, the outlook for pulmonary arterial hypertension patients is changing. This talk will discuss the currently available therapies for patient with pulmonary arterial hypertension whilst also looking to the future of disease management.
Despite potentially curable options for chronic thromboembolic pulmonary hypertension, this disease is often overlooked by respiratory physicians. Current management of CTEPH with a focus on how to identify patients and whom to refer to specialist services will be explored.
Curriculum mapping
Speciality Capabilities in Practice 2 – Managing integrated respiratory medicine across the primary and secondary care interface including management of long-term disease.
Speciality Capabilities in Practice 5 - Tertiary subspecialities interface: managing patients across the secondary and tertiary interface; in particular patients with lung and heart transplants and pulmonary hypertension.
Speciality Capabilities in Practice 6 – Managing the use of drugs and therapeutic modalities specific to the practice of respiratory medicine.